Patents by Inventor Huanzhang Lu

Huanzhang Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8440421
    Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infraction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 14, 2013
    Inventors: John G. Coles, Gregory Hannigan, Huanzhang Lu
  • Publication number: 20120177627
    Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infraction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal.
    Type: Application
    Filed: March 2, 2012
    Publication date: July 12, 2012
    Inventors: John G. COLES, Gregory Hannigan, Huanzhang Lu
  • Patent number: 7923218
    Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infarction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal.
    Type: Grant
    Filed: May 29, 2006
    Date of Patent: April 12, 2011
    Inventors: John G. Coles, Gregory Hannigan, Huanzhang Lu
  • Publication number: 20110059479
    Abstract: The invention relates to a process for identification, amplification and differentiation of cardiac stem cells by utilizing an ILK based protocol. The invention further relates to a process for post myocardial infarction (IVII) remodeling by way of the integrin linked kinase (ILK) signaling pathway. Still further, the invention relates to a process for affecting an ability to control and/or manipulate stem cell frequency, cellular fate, self-renewal, multilineage differentiation, and potential for oncogenesis in cardiac tissue derived from embryonic stem cells, fetal tissue or adult tissue comprising modulation of ILK signaling amplification whereby stem cell renewal and expansion results.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 10, 2011
    Inventors: John G. COLES, Gregory Hannigan, Huanzhang Lu
  • Publication number: 20090203769
    Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process for mediating a broadly adaptive form of human cardiac hypertrophy and a protective process for post myocardial infarction (MI), both comprising illiciting an overexpression of ILK, are described. Upregulation of ILK is also used in a process for affecting ILK mediated reduction of infarct size and beneficial increase in the left ventricular mass post MI.
    Type: Application
    Filed: May 29, 2006
    Publication date: August 13, 2009
    Inventors: John G. Coles, Gregory Hannigan, Huanzhang Lu
  • Publication number: 20080274491
    Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infarction (MI) remodeling comprising illiciting an overexpression of ILK, is described.
    Type: Application
    Filed: May 29, 2006
    Publication date: November 6, 2008
    Inventors: John G. Coles, Gregory Hannigan, Huanzhang Lu